IP Group news 0

IP Group plc (LSE: IPO) (“IP Group” or "the Group"), which invests in breakthrough science and technology companies with the potential to create a better future for all, is delighted to announce the appointment of Michael Queen as Non-executive Director and Chair Designate. The appointment concludes the Chair succession process announced last year and supports IP Group’s continued focus on long‑term value creation and scaling institutional capital.

Michael will succeed Sir Douglas Flint, CBE, as Chair of the Board following IP Group’s Annual General Meeting on 18 June 2026 when Sir Douglas will retire from the Board after almost eight years of service.

Greg Smith, Chief Executive of IP Group, said: “I am delighted to welcome Michael to the Board at a time of growing opportunity for IP Group. He brings deep investment and leadership experience, with a strong track record in scaling institutional capital platforms, which aligns closely with our strategy as we continue to grow funds under management and support our portfolio through their next phase of development. On behalf of the Board and our colleagues, I would also like to thank Sir Douglas for the enormous contribution he has made to IP Group over many years and to wish him every success in the future.”

Michael Queen said: “IP Group is a nationally significant platform that invests in and supports leading scientific innovation. I’m excited to be given the opportunity to chair the Group as it scales its model and I look forward to working with the team to help deliver value for all stakeholders.”

Sir Douglas Flint said: “I look forward to working with Michael over the next few weeks to support his transition into the role of Chair following the AGM. Michael’s deep knowledge of private markets and venture investment will be invaluable to support the Group’s realisation of value from the portfolio and its refresh, as will his understanding of the University sector in the UK. I will leave the Group as a loyal and committed shareholder reflecting on the privilege it has been to work alongside such a talented executive team and Board. I would like to thank the Board, the leadership team and the wider IP Group team for their commitment and support throughout my tenure."

Michael was formerly Chief Executive of 3i Group plc, the global investment company where after 25 years he retired in 2012 having developed 3i’s activities in the infrastructure sector through founding 3i Infrastructure plc. He is currently Chair of Coller Capital Ltd, a UK based international Private Equity Group, Pro-Chancellor of the University of Surrey, Chair of Thames Tideway Tunnel and a non-executive director of TAQA, a Middle East based industrial group.

He has extensive experience in the public and private sectors, having been a member of the Prime Ministers Business Advisory Group from 2010-2012 and having been seconded to HM Treasury in 1994 to help to develop the potential for the Private Finance Initiative in the NHS as Head of the NHS Private Finance Unit. In 2002 Michael was Chairman of the British Venture Capital Association and he was also President of Surrey 100, a Business Angel Group attached to the University of Surrey from 2012 to 2018. Michael has a BA (Hons) Industrial Economics from Nottingham University and is a Chartered Accountant.

This announcement is made pursuant to Listing Rule 6.4.6R. There are no other details required to be disclosed under Listing Rule 6.4.8R.

For more information, please contact:

 

IP Group plc	www.ipgroupplc.com
Liz Vaughan-Adams, Communications	+44 (0) 20 7444 0062/+44 (0) 7967 312125
Portland
Lewis Bendall-Craft	+44 (0) 7931 973950

 

Notes for editors

 

About IP Group

 

IP Group accelerates the impact of science for a better future. As the most active UK based, early stage science and technology investor, we develop and support some of the world’s most exciting businesses in healthtech, deeptech and cleantech. Including through Parkwalk, the UK's largest growth EIS fund manager, we back world-changing innovation emerging in leading universities and research institutions. Our specialist investment team combines sector expertise with an international approach. Together we have a strong track record of success, having backed high-profile companies including Oxford Nanopore Technologies plc, Hinge Health, Featurespace, First Light Fusion, Hysata, and Oxa. IP Group is listed on the Main Market of the London Stock Exchange under the code IPO.

 

For more information, please visit our website at www.ipgroupplc.com.

 

ENDS